SEGOVA Program is the most advanced, innovative and safest autologous method of organic regeneration of the gonads. It requires the use of patients own cells and growth factors to re-establish and enhance ovarian function and hormone production, thus improving reproductive health and whole-body functioning. It restores ovarian function, helps delaying menopause and prevents the age-related diseases.

The main advantage of SEGOVA is based on autologous, organic regeneration of the gonads, the organs which change the most through ageing. Gonads, ovaries and testes, influence the functioning and structure of all other tissues and organs within the organism.


Age-related ovarian dysfunction and fertility decline in women has emerged as an indication for ovarian rejuvenation as the age at which women now attempt their first pregnancy has been steadily rising over the last decades. Female fertility naturally decreases significantly after the age of 35 years, causing poor oocyte quality, abnormalities in the meiotic spindle, chromosome misalignment and shortened telomeres.

There are different groups of women seeking fertility preservation or ovarian rejuvenation, including patients with the hematological malignancies, women with premature ovarian failure and infertility as well as those who wish to postpone childbearing for various personal reasons, with age becoming the main threat to their fertility.

Following the SEGOVA procedure, restored ovarian tissue takes over the role that it had before and begins the production of its own sex hormones. The lost functions of the ovaries are re-established and all other organs and tissues in the body are rejuvenated and their work is improved.


SEGOVA Program consists of several separate procedures integrated in a common project aimed to support, increase or create elements necessary for normal gonadal function.

The first letters of the SEGOVA abbreviation in fact represent the specific procedures:

S – Stem cell therapy
Cell therapy which uses autologous stem cells – cells obtained from the patients’ own body. The aim is to create new or incite existing non-differentiated gonadal stem cells – which are to be developed into new oocytes or sperm cells and the hormone-producing cells.

E – Energy mitochondrial boosting
Stem cell therapy is correcting mitochondrial function in existing cells However, boosting mitochondrial energy production in gonadal cells with a specific physical exercise regime – HIIT (High Intensity Interval Training) is a combination of highly intensive, intermittent, specific anaerobic exercise.

G – Growth factor PLPR therapy
Growth factors are essential mediators in gonadal control mechanisms. These growth factors are obtained from the patient’s own blood and used to treat gonadal tissue. They act by controlling the creation and growth of eggs and the surrounding cells responsible for hormone production. In recent years, ovarian revitalization methods have been applied worldwide in order to improve the hormonal and reproductive conditions of the patient and thus their quality of life. PLRP is a separated part of the whole blood where the high platelet level is concentrated, but with growth factors of 3 to 5 times the plasma concentration. Growth factors are found in the granules and they play an important role in cell proliferation, chemotaxis, promotion of angiogenesis and differentiation of mesenchymal and other types of cells.

OVA – Ovarian in Vitro Activation
The production of eggs – oogenesis, is dependent on proper genetic control. Hippo the signaling pathway is essential for maintaining optimum organ size. It contains several negative growth regulators. The AKT the signaling pathway has a key role in the initiation of follicle growth. The ovarian in vitro activation represents the autologous genetic treatment of the gonadal tissue in order to restore both reproductive and endocrine functions of the ovary.

Procedure by days

SEGOVA procedure day 0
Arrival to your selected SEGOVA Program clinic and time with nutritional and physical specialists.

SEGOVA procedure day 1
The SEGOVA procedure begins by taking the patient’s blood, from which the cells rich in growth factors are separated and prepared for activation. This is followed by a gonadal biopsy performed using a minimally invasive procedure under local or general anesthesia. The obtained gonadal tissue is micro fragmented.

SEGOVA procedure day 2
A resting day for the patient at the hospital. Meanwhile the tissue particles are being incubated in growth factors from previously obtained blood cells. It is done in a specifically controlled conditions in a laboratory.

SEGOVA procedure day 3
This phase requires bone marrow sampling by performing the puncture of the shinbone. Bone marrow is processed to separate the patients stem cells. The ultrasound 4D the color guided needle gonadal re-transplantation is used to insert previously processed gonadal tissue with growth factors. The same approach is for the next step – stem cells application into the gonads. Following this the patient is discharged from the clinic the same afternoon and able to return to their regular activities or travel.


SEGOVA procedure for men is a safe, innovative method, based on autologous, organic regeneration of the gonads. It requires the use of patients own cells and growth factors to re-establish and enhance testicular function and hormone production, thus improving reproductive health and whole-body functioning (skin, face, muscles, bones, blood vessels and other). It helps delaying andropause and prevents the age-related diseases.

The age-related decline in testosterone along with the associated symptoms has been referred to as male menopause or the andropause. Partial androgen deficiency and the decline in testosterone seen in ageing men has clinical implications. Along with the decline in testosterone, some men experience symptoms that include: fatigue, weakness, depression, sexual dysfunction. Standard medical therapy today – Testosterone replacement is connected with potential risks and side effects.

SEGOVA Program for men follows the standard set of SEGOVA procedures and includes the standard follow up program.

Follow up program

SEGOVA Program follow up begins at the end of the SEGOVA procedure completion. We provide test results upon your departure and following the first month of the procedure we as you to perform certain blood work tests and share the results with us. Usually the same, sometimes additional, tests are then performed at quarterly intervals during the period of up to two years if not otherwise requested by SEGOVA medical team and agreed with the patient.


SEGOVA has a favourable effect on the endocrine status and on the reproductive outcome of patients in post-menopause. The total results of ultrasonography for 73 patients show that after the re-transplantation 64% of patients had the presence of a follicle.


The age of the oldest patient who underwent our procedure is 58 years old.

The procedure is performed in Europe at the private hospitals St James Hospital in Sliema, Malta and Medigroup Hospital in Belgrade, Serbia.

Yes, all of our staff (doctors, nurses and administration) are English speaking. Upon request, we can also provide simultaneous translators in Frech, Italian, German, Spanish, Arabic and Russian languages.

At least about two weeks ahead. That is the optimal time for all the preparatory analysis to be done and for contract and payment to be made.

No, the SEGOVA procedure can be done throughout the complete cycle.

Please view the complete list of required tests here (link to download PDF)

All of the required tests can be done at our clinics several days prior to the procedures. However, if you choose to do the test with us you should plan to arrive a few days earlier to Serbia or Malta.

Yes, the positive results could imply the existence of a certain condition which must be treated prior to the SEGOVA procedure.

Duration of the whole SEGOVA treatment is actually 4 days, with the first day being the day of your arrival and the subsequent three days are the days you would be spending at the hospital. Discharge from the hospital is usually on the third day of the procedure in the late afternoon.

SEGOVA Program costs include a complete hospital stay (apartment, medication, team, anaesthesia etc.) and the follow up program of up to two years which includes specific training program and individualised nutritional plan and supplement intake for at least 6 to 12 months. Tests, travel and accommodation outside of hospital stay are not included.

We measure the before and after results of the hormonal status, hormonal growth, follicle growth, egg cell retrieval etc. The basis of our follow up program is that we ask our patients to perform sex hormone analysis and send us scans of their ovaries monthly and we tailor our follow up program and next steps according to their results.

First results can be observed at 6 to 12 months following the procedure.

Total of more than 130 patients underwent some form of ovarian rejuvenation procedure with us (35 PLRP, 21 SEGO, 49 SEGOVA). Of all the patients who had complete SEGOVA procedure 36 of them were monitored for at least one year after the procedure. Currently the results indicate that 17 women (47% pts.) had oocytes (45) and 14 (39% pts.) had embryos.                                     

The efficiency of the treatment is directly dependent not only on the age and initial diagnosis, but also on the level of the biotechnology we use. We have observed positive effects in less than half of the patients who had only PLRP treatment. In the responders, we had 20% cumulative pregnancy rate in a 2 years period.

Using PLRP with stem cells gave a hormonal improvement in 70% of patients, and when performing complete SEGOVA procedure, we have seen improvements in 88% of patients. The average age for the SEGOVA patients was 43,9 years of age. The average age of the pregnant group was around 42, although we had a pregnancy in one 49 year old patient.

SEGOVA reproductive results for 2018 show that SEGOVA procedure was performed in 28 patients. In 10 patients we had oocytes/embryos (some of them vitrified) we have 7 pregnancies and 5 babies.

Yes, the contract must be signed and all payments must be made in advance, prior to your travel and check into a hospital as this is our company policy.

The rate of complications that we had after SEGOVA procedures is lower than 1%. We had one minor postoperative complication (an inflammatory process) which has been resolved within 2 days.